Topical Treatment With Fresh Human Milk Versus Emollient on Atopic Eczema Spots in Young Children
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02381028 |
Recruitment Status :
Completed
First Posted : March 6, 2015
Last Update Posted : March 6, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Atopic Eczema | Other: Human milk and emollient: Apobase creme® (Actavis Norway AS) Other: Emollient: Apobase creme® (Actavis Norway AS) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 9 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Single (Investigator) |
Primary Purpose: | Treatment |
Official Title: | Topical Treatment With Fresh Human Milk Versus Emollient on Atopic Eczema Spots in Young Children: A Small, Randomized, Split Body, Controlled, Blinded Pilot Study |
Study Start Date : | October 2008 |
Actual Primary Completion Date : | November 2010 |
Actual Study Completion Date : | November 2010 |

Arm | Intervention/treatment |
---|---|
Experimental: Study area
Human milk and emollient: Apobase creme® (Actavis Norway AS)
|
Other: Human milk and emollient: Apobase creme® (Actavis Norway AS)
Topical application of human milk followed by emollient Other: Emollient: Apobase creme® (Actavis Norway AS) Topical application of emollient |
Active Comparator: Control area
Emollient: Apobase creme® (Actavis Norway AS)
|
Other: Emollient: Apobase creme® (Actavis Norway AS)
Topical application of emollient |
- Proportional change in area of the eczema spot from baseline [ Time Frame: four weeks ]The primary outcome was proportional change in area (cm2) of the eczema spot from baseline, as measured by Visitrak™ (Smith & Nephew), a portable device used to measure the area of wounds.
- Transmission of bacteria from mother's milk to eczema spots in the child [ Time Frame: four weeks ]The secondary outcome was to assess transmission of bacteria from mother's milk to eczema spots in the child.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 6 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Children with atopic eczema according to Hanifin and Rajkas criteria with a mother breastfeeding the child or a sibling.
- The eczema spots in the treatment and control areas were to be similar in features and extent as well as being localized on contralateral parts of the body.
Exclusion Criteria:
- Children were excluded if the severity of the eczema spots indicated need for treatment with antibiotics and/or steroids.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02381028
Principal Investigator: | Teresa L Berents, MD | Oslo University Hospital |
Responsible Party: | Teresa Løvold Berents, Medical doctor, Oslo University Hospital |
ClinicalTrials.gov Identifier: | NCT02381028 |
Other Study ID Numbers: |
08/318b |
First Posted: | March 6, 2015 Key Record Dates |
Last Update Posted: | March 6, 2015 |
Last Verified: | March 2015 |
Atopic eczema Human milk Topical treatment Children |
Dermatitis, Atopic Eczema Dermatitis Skin Diseases Skin Diseases, Eczematous Skin Diseases, Genetic |
Genetic Diseases, Inborn Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Emollients Dermatologic Agents |